Claims for Patent: 12,280,025

Summary for Patent: 12,280,025

Title:	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Abstract:	A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US18/367,412
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,280,025
Patent Claims:	1. A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which comprises: administering to the subject, once daily, a formulation means for oral delivery of colchicine, wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject, and wherein the composition reduces the risk of the cardiovascular event by a greater percentage than a composition that does not include colchicine and/or a salt thereof. 2. The method of claim 1, wherein the formulation means is in a form of a tablet or a capsule. 3. The method of claim 2, wherein the formulation means is in a form of a tablet. 4. The method of claim 1, wherein the risk of the least one cardiovascular event is reduced by at least about 30%. 5. The method of claim 1, wherein the formulation means is in a form of a liquid dose, a gel, or a powder. 6. The method according to claim 1, wherein the at least one cardiovascular event is chosen from acute coronary syndrome, out-of-hospital cardiac arrest, and noncardioembolic ischemic stroke. 7. The method of claim 1, wherein the subject has at least one history chosen from a previous diagnosis of diabetes, past myocardial infarction, unstable angina, coronary bypass surgery, and coronary angioplasty. 8. The method of claim 1, wherein the subject is from about 35 to about 85 years of age. 9. The method of claim 1, wherein the at least one cardiovascular event is cardiac arrest. 10. The method of claim 1, wherein the at least one cardiovascular event is coronary revascularization. 11. The method of claim 1, wherein the at least one cardiovascular event is unstable angina requiring hospitalization. 12. The method of claim 11, wherein the at least one cardiovascular event is MI. 13. The method of claim 1, wherein the at least one cardiovascular event is stroke. 14. The method of claim 1, wherein the at least one cardiovascular event is cardiovascular death in the subject. 15. The method of claim 1, wherein the subject is administered the formulation means daily for at least 24 months. 16. The method of claim 1, wherein the subject is administered the formulation means daily for at least 36 months. 17. The method of claim 1, wherein the subject is administered the formulation means daily for at least 44 months.